C4 Therapeutics earnings were -$107.9M for the trailing 12 months ending Jun 30, 2024, with N/A growth year over year. The latest CCCC earnings report on Jun 30, 2024 announced Q2 2024 earnings of -$17.7M, down 37.5% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, CCCC reported annual earnings of -$132.5M, with 3.4% growth. The next CCCC earnings date is Oct 30, 2024.
What were C4 Therapeutics's earnings last quarter?
On CCCC's earnings call on Invalid Date, C4 Therapeutics (NASDAQ: CCCC) reported Q2 2024 earnings per share (EPS) of -$0.26, up 64.38% year over year. Total CCCC earnings for the quarter were -$17.72 million. In the same quarter last year, C4 Therapeutics's earnings per share (EPS) was -$0.73.
The next CCCC earnings call is Invalid Date. Add CCCC to your watchlist to be reminded of C4 Therapeutics's next earnings date.
Is C4 Therapeutics profitable or losing money?
As of the last C4 Therapeutics earnings report, C4 Therapeutics is currently losing money. C4 Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2024 was -$107.87 million, a 22.87% decrease year over year.
What was CCCC's earnings growth in the past year?
As of C4 Therapeutics's earnings date in Invalid Date, C4 Therapeutics's earnings has grown year over year. CCCC earnings in the past year totalled -$107.87 million.
What are C4 Therapeutics's earnings expectations?
The current EPS estimate for C4 Therapeutics's earnings report in Invalid Date is -$0.38.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.